7li3 Citations

Structural analysis of the full-length human LRRK2.

Cell 184 3519-3527.e10 (2021)
Related entries: 7lht, 7lhw, 7li4

Cited: 53 times
EuropePMC logo PMID: 34107286

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are commonly implicated in the pathogenesis of both familial and sporadic Parkinson's disease (PD). LRRK2 regulates critical cellular processes at membranous organelles and forms microtubule-based pathogenic filaments, yet the molecular basis underlying these biological roles of LRRK2 remains largely enigmatic. Here, we determined high-resolution structures of full-length human LRRK2, revealing its architecture and key interdomain scaffolding elements for rationalizing disease-causing mutations. The kinase domain of LRRK2 is captured in an inactive state, a conformation also adopted by the most common PD-associated mutation, LRRK2G2019S. This conformation serves as a framework for structure-guided design of conformational specific inhibitors. We further determined the structure of COR-mediated LRRK2 dimers and found that single-point mutations at the dimer interface abolished pathogenic filamentation in cells. Overall, our study provides mechanistic insights into physiological and pathological roles of LRRK2 and establishes a structural template for future therapeutic intervention in PD.

Reviews - 7li3 mentioned but not cited (2)

  1. LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights. Skelton PD, Tokars V, Parisiadou L. Cells 11 169 (2022)
  2. Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. Thakur G, Kumar V, Lee KW, Won C. Genes (Basel) 13 1426 (2022)

Articles - 7li3 mentioned but not cited (1)



Reviews citing this publication (14)

  1. LRRK2 and idiopathic Parkinson's disease. Rocha EM, Keeney MT, Di Maio R, De Miranda BR, Greenamyre JT. Trends Neurosci 45 224-236 (2022)
  2. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease. Wojewska DN, Kortholt A. Biomolecules 11 1101 (2021)
  3. LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease. Chang EES, Ho PW, Liu HF, Pang SY, Leung CT, Malki Y, Choi ZY, Ramsden DB, Ho SL. Transl Neurodegener 11 10 (2022)
  4. Structural Biology of LRRK2 and its Interaction with Microtubules. Leschziner AE, Reck-Peterson SL. Mov Disord 36 2494-2504 (2021)
  5. Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease. Smith LJ, Lee CY, Menozzi E, Schapira AHV. Front Neurol 13 971252 (2022)
  6. Neuroinflammation in Parkinson's Disease: From Gene to Clinic: A Systematic Review. Castillo-Rangel C, Marin G, Hernández-Contreras KA, Vichi-Ramírez MM, Zarate-Calderon C, Torres-Pineda O, Diaz-Chiguer DL, De la Mora González D, Gómez Apo E, Teco-Cortes JA, Santos-Paez FM, Coello-Torres MLÁ, Baldoncini M, Reyes Soto G, Aranda-Abreu GE, García LI. Int J Mol Sci 24 5792 (2023)
  7. Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease. Turski P, Chaberska I, Szukało P, Pyska P, Milanowski Ł, Szlufik S, Figura M, Hoffman-Zacharska D, Siuda J, Koziorowski D. Front Neurosci 16 971270 (2022)
  8. The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson's Disease. Zhang M, Li C, Ren J, Wang H, Yi F, Wu J, Tang Y. Front Aging Neurosci 14 909303 (2022)
  9. Perspective on the current state of the LRRK2 field. Taymans JM, Fell M, Greenamyre T, Hirst WD, Mamais A, Padmanabhan S, Peter I, Rideout H, Thaler A. NPJ Parkinsons Dis 9 104 (2023)
  10. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2. Park Y, Liao J, Hoang QQ. Trends Biochem Sci 47 1038-1047 (2022)
  11. Insights into the cellular consequences of LRRK2-mediated Rab protein phosphorylation. Fasiczka R, Naaldijk Y, Brahmia B, Hilfiker S. Biochem Soc Trans 51 587-595 (2023)
  12. LRRK2 Structure-Based Activation Mechanism and Pathogenesis. Zhang X, Kortholt A. Biomolecules 13 612 (2023)
  13. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease. Ito G, Utsunomiya-Tate N. Biomolecules 13 845 (2023)
  14. An Update on the Interplay between LRRK2, Rab GTPases and Parkinson's Disease. Komori T, Kuwahara T. Biomolecules 13 1645 (2023)

Articles citing this publication (36)